Madrigal Pharmaceuticals Inc.
- Address
- 200 Barr Harbor Drive Suite 400
Sponsor Overview
Specializations
Non-Alcoholic Steatohepatitis and Metabolic Liver Disease
Madrigal Pharmaceuticals Inc. focuses on clinical research in NASH, with trials centered on disease activity, histological improvement, and prevention of progression in adults with fatty liver-related inflammation and fibrosis.
- Non-Alcoholic Steatohepatitis
- NAFLD activity score
- Fibrosis
- Liver biopsy
The sponsor’s studies examine liver tissue changes associated with NASH, including resolution of inflammatory features and improvement in scarring.
NASH Cirrhosis and Advanced Liver Disease
Its research also extends to NASH cirrhosis, addressing advanced chronic liver disease and clinical outcomes linked to hepatic decompensation and transplant risk.
- NASH cirrhosis
- Hepatic decompensation
- Liver transplant
- Model for End-stage Liver Disease (MELD) score
These trials focus on patients with well-compensated cirrhosis and track major liver-related outcomes relevant to advanced disease management.
Cardiometabolic and Liver-Related Outcomes
The sponsor’s trial portfolio includes outcomes research that links liver disease with broader cardiometabolic risk, including mortality and major clinical events.
- Liver-related mortality
- Cardiovascular mortality
- Composite clinical outcomes
- Hepatic encephalopathy
Clinical endpoints reflect interest in events that capture both hepatic progression and systemic consequences of advanced metabolic liver disease.
Oral Therapeutics for Liver Disease
Madrigal Pharmaceuticals Inc. is active in research on oral therapy for liver disease, with studies evaluating long-term safety and treatment response in patients receiving resmetirom and MGL-3196.
- Resmetirom
- MGL-3196
- Long-term safety
- Treatment response
Research activity includes follow-up beyond initial treatment periods to assess sustained effects in NASH and NASH cirrhosis.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Resmetirom on Liver-Related Outcomes in Patients with Well-Compensated Non-Alcoholic Steatohepatitis Cirrhosis: A Phase 3 Randomized Study |  Belgium France Germany Italy Spain | Not Recruiting |
| Phase 3 Multinational Study of Resmetirom in Non-Alcoholic Steatohepatitis Patients to Assess NASH Resolution and Fibrosis Progression Prevention |  Austria Belgium France Germany Hungary Italy Poland Spain | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 67 sites across their trial portfolio.
Therapeutic Focus
- 1.Digestive System Diseases2 trials280 other sponsors
Partnered Research Centres
67 centres- Address
- Via Consolare Valeria N 1, 98124 Messina
- Address
- Deltalaan 1, 8800 Roeselare
- Address
- Buitenring-Sint-Denijs 30, 9000 Ghent
- Address
- Via Cherasco 15, 10126 Turin
- Address
- Via Del Vespro 129, 90127 Palermo
- Address
- Largo Giovanni Alessandro Brambilla 3, 50134 Florence
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Madrigal Pharmaceuticals Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.